Altimmune (NASDAQ:ALT – Get Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $12.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 101.01% from the company’s previous close.
Other analysts have also issued research reports about the company. Stifel Nicolaus initiated coverage on Altimmune in a report on Wednesday, January 8th. They issued a “buy” rating and a $18.00 price target for the company. William Blair reissued a “market perform” rating on shares of Altimmune in a research report on Friday. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $20.83.
Read Our Latest Research Report on Altimmune
Altimmune Trading Up 0.8 %
Altimmune (NASDAQ:ALT – Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. As a group, equities research analysts predict that Altimmune will post -1.35 EPS for the current fiscal year.
Insider Activity
In other news, CFO Gregory L. Weaver acquired 10,000 shares of the business’s stock in a transaction dated Thursday, March 13th. The shares were purchased at an average price of $5.20 per share, with a total value of $52,000.00. Following the transaction, the chief financial officer now directly owns 10,000 shares in the company, valued at approximately $52,000. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 4.10% of the company’s stock.
Institutional Investors Weigh In On Altimmune
Institutional investors have recently bought and sold shares of the company. Larson Financial Group LLC purchased a new stake in shares of Altimmune during the 3rd quarter valued at $31,000. SBI Securities Co. Ltd. purchased a new stake in Altimmune in the fourth quarter valued at about $45,000. Virtus ETF Advisers LLC acquired a new stake in Altimmune in the fourth quarter worth about $60,000. Cullen Frost Bankers Inc. purchased a new stake in shares of Altimmune during the fourth quarter worth about $72,000. Finally, 180 Wealth Advisors LLC purchased a new stake in shares of Altimmune during the fourth quarter worth about $78,000. 78.05% of the stock is currently owned by institutional investors and hedge funds.
Altimmune Company Profile
Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.
Featured Articles
- Five stocks we like better than Altimmune
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Kohl’s Posts Another Kitchen Sink Quarter, But New CEO Has a Plan
- Why is the Ex-Dividend Date Significant to Investors?
- Southwest Airlines Could Triple From Here—Here’s How
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Salesforce: An Early AI Opportunity With Long-Term Potential
Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.